Bavencio (avelumab)

She received carboplatin/paclitaxel plus avelumab, followed by pegylated liposomal doxorubicin and weekly paclitaxel. This case illustrates that T-DXd can induce deep and durable remission in HER2-positive, dMMR metastatic serous endometrial cancer after multiple lines of therapy. It adds real-world evidence supporting further investigation of HER2-directed antibody-drug conjugates in gynaecologic malignancies, and underscores the need for confirmatory trials and refined biomarker-driven patient selection.

The efficacy of pembrolizumab and pembrolizumab-lenvatinib regimen appears promising. However, studies with larger sample size, longer follow-up and comparative design with subgroup analysis based on differences in microsatellite repair mechanisms are needed for proper therapeutic positioning.

ICIs optimal treatment duration remains uncertain. Literature on metastatic melanoma suggests that discontinuing ICIs after a complete response rarely leads to recurrence. Prospective studies and emerging biomarkers, such as circulating tumor DNA, may help tailor treatment decisions.

P2, N=48, Recruiting, Samsung Medical Center

P2, N=6, Active, not recruiting, Emory University | Recruiting --> Active, not recruiting | N=24 --> 6

P1, N=19, Active, not recruiting, University of Oklahoma | Trial completion date: Sep 2025 --> Feb 2026

P1/2, N=173, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Sep 2025 --> Apr 2026

Compound 14a also effectively restored T cell proliferation suppressed by 5'-N-ethylcarboxamidoadenosine (NECA) and exhibited superior T cell-mediated cytotoxicity in coculture systems with A1R- and PD-L1-expressed cancer cells compared with ciforadenant (A2AR antagonist) and etrumadenant (A2AR/A2BR dual antagonist). Moreover, the combination of compound 14a with avelumab, an anti-PD-L1 antibody, resulted in enhanced infiltration of effector T cells and significantly increased the CD8+/Treg ratio in the CT26 syngeneic mouse model, substantially inhibiting tumor growth. Therefore, compound 14a is a promising candidate for multitargeted immunomodulation in cancer immunotherapy.

P2, N=0, Withdrawn, Mirror Biologics, Inc. | N=50 --> 0 | Trial completion date: Nov 2025 --> Nov 2028 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2025 --> Jun 2028

P1, N=17, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Dec 2025 --> Sep 2026 | Trial primary completion date: Dec 2025 --> Sep 2026

First-line avelumab 800 mg IV every two weeks plus axitinib was initiated; in July 2025 axitinib was reduced to 5 mg once daily. After eight cycles, interim CT (August 2025) demonstrated regression with no locoregional recurrence. This case highlights continued vigilance and prompt biopsy of atypical eyelid lesions.

Disproportionality signals were observed for six ICI monotherapies and one combination therapy: atezolizumab (ROR 6.84; 95% CI: 5.58-8.40), avelumab (ROR 5.54; 95% CI: 2.64-11.63), nivolumab (ROR 4.37; 95% CI: 3.64-5.25), pembrolizumab (ROR 3.44; 95% CI: 2.88-4.10), durvalumab (ROR 2.03; 95% CI: 1.12-3.66), ipilimumab (ROR 2.05; 95% CI: 1.07-3.94), and the combination therapy of nivolumab and ipilimumab (ROR 4.56; 95% CI: 3.56-5.83). Firth multivariate logistic regression analysis identified several independent risk factors, including advanced age (>65 years), malignant renal neoplasm, malignant mesothelioma, and the concomitant use of bevacizumab or lenvatinib...Additionally, a literature review of 18 cases provided supplementary information on the clinical features. This study provides vital pharmacovigilance insights regarding nephrotic syndrome related to ICIs, enhancing the understanding of its clinical implications.